Why the study?
TRAIL is known to be involved in the progression of pulmonary hypertension and its knockout has an inhibitory effect, but the underlying mechanism is not completely clear.
Does anti-TRAIL antibody treatment reduce pulmonary hypertension and vascular remodeling in hypoxia-induced PH mice?
Does anti-TRAIL antibody treatment reduce pulmonary hypertension and vascular remodeling in hypoxia-induced PH mice?
Anti-TRAIL antibody attenuates hypoxia-induced pulmonary hypertension and vascular remodeling in mice by inhibiting Smad2/3 phosphorylation.
Introduction Previous studies have found that tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) was involved in the progression of pulmonary hypertension (PH), and TRAIL knocking (KO) has an inhibitory effect on PH, but its mechanism is not completely clear. Methods The effects of TRAIL on the accumulation of extracelluar matrix (ECM), which is one of the most important processes of vascular remodeling, were observed in mice and isolated pulmonary artery smooth muscle cells (PASMCs). In vivo, mice were divided into four groups: Control group (n = 5), hypoxia-induced PH mice group (n = 8), anti-TRAIL antibody (TRAIL-Ab) treatment group (n = 8) and IgG antibody (IgG) group (n = 8). The effects of TRAIL-Ab on ECM expression in hypoxic induced PH were researched; in vivo, PASMCs were divided into three groups: Control group, hypoxia-induced group, TRAIL-Ab group. Expressions of p-Smad2/3 and p-Smad1/5/8 were compared among the three groups. Results Hypoxia-induced PH mice had significant increases in right ventricle systolic pressure (RVSP) (P < 0.001), right ventricular hypertrophy (RVH) (P = 0.007), vascular stenosis (P < 0.001) compared with controls. Mice with anti-TRAIL antibody had lower levels in RVSP (P < 0.001), RVH (P < 0.001), vascular stenosis (P < 0.001) than PH mice. Besides, the TRAIL-Ab significantly inhibited the phosphorylation of Smad2/3 compared with hypoxia-induced group. Conclusion TRAIL regulates the accumulation of ECM in pulmonary artery by activating pSmad2/3.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2019) studied Pulmonary hypertension (n=29). Anti-TRAIL antibody vs. Hypoxia-induced PH mice / IgG antibody was evaluated on Right ventricle systolic pressure (RVSP), right ventricular hypertrophy (RVH), and vascular stenosis (p=<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: